Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach-Reference-Cited by-同舟云学术

Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach

Published:2014-02-15 Issue:3 Volume:32 Page:542-548
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Ocean Allyson J.,Christos Paul,Sparano Joseph A.,Shah Manish A.,Yantiss Rhonda K.,Cheng Jonathan,Lin Juan,Papetti Michael,Matulich Dan,Schnoll-Sussman Felice,Besanceney-Webler Christen,Xiang Jenny,Ward Maureen,Dilts Kaili Temple,Keresztes Roger,Holloway Shannon,Chen Eric X.,Wright John J.,Lane Maureen E.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-014-0070-0.pdf

Reference19 articles.

1. Munro AJ, Niblock PG (2010) Cancer research in the global village. Lancet 376(9742):659–660

2. Brown LM, Devesa SS, Chow WH (2008) Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 100(16):1184–1187

3. Bang YJ et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697

4. Power DG, Kelsen DP, Shah MA (2010) Advanced gastric cancer–slow but steady progress. Cancer Treat Rev 36(5):384–392

5. Reinstein E, Ciechanover A (2006) Narrative review: protein degradation and human diseases: the ubiquitin connection. Ann Intern Med 145(9):676–684

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ER stress and the unfolded protein response in gastrointestinal stem cells and carcinogenesis;Cancer Letters;2024-04

2. UPS: Opportunities and challenges for gastric cancer treatment;Frontiers in Oncology;2023-04-03

3. The hypoxia-inducible factor-1α in stemness and resistance to chemotherapy in gastric cancer: Future directions for therapeutic targeting;Frontiers in Cell and Developmental Biology;2023-02-08

4. Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy;Cellular Oncology;2022-09-23

5. Gastric Cancer Heterogeneity and Clinical Outcomes;Technology in Cancer Research & Treatment;2020-01-01